Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page footer now shows Revision: v3.5.4, replacing v3.5.3, indicating a new build of the page rendering. No changes to study content are reflected in this update.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe page indicates an updated site revision number (from v3.5.2 to v3.5.3). This reflects a versioning update of the page itself rather than a substantive change to the trial information.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision updated to v3.5.2; the previous v3.5.0 revision was removed.SummaryDifference0.1%

- Check78 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check86 days agoChange DetectedRevision: v3.4.3 has been added, and Revision: v3.4.2 has been removed.SummaryDifference0.1%

- Check114 days agoChange DetectedThe update includes a minor site-version revision (Revision: v3.4.2) and removal of a government-operating-status notice; no study content, eligibility criteria, or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.